Latest Articles
CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells - themarijuanaherald.com
CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells themarijuanaherald.com
Published: Sept. 23, 2026, 5:01 p.m.
CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells - The Marijuana Herald
CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells The Marijuana Herald
Published: Sept. 23, 2026, 5:01 p.m.
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - Clinical Oncology News
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer Clinical Oncology News
Published: Aug. 3, 2026, 3:32 p.m.
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - clinicaloncology.com
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer clinicaloncology.com
Published: Aug. 3, 2026, 3:31 p.m.
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial - Yahoo Finance
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial Yahoo Finance
Published: July 27, 2026, 10:08 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Sahm
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Sahm
Published: July 16, 2026, 10:27 a.m.
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk
Published: July 15, 2026, 11:49 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Benzinga
Published: July 15, 2026, 5:25 p.m.
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive
Published: July 15, 2026, 3:58 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace
Published: July 15, 2026, 3:11 p.m.
Link copied to clipboard!